Articles On Imugene (ASX:IMU)

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

The company has enhanced its portfolio with a novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.

The Imugene Limited (ASX: IMU) share price has continued its positive run on Tuesday. At the time of writing, the immuno-oncology company’s shares are up over 13% to an all-time high of 46 cents. This latest gain means the Imugene share pr...

Biotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gains in May which has seen its share price rise by almost 500 per cent over the past 12 months. Each week, Stockhead recaps ASX stocks that are...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

The Imugene Limited (ASX: IMU) share price hit an all-time high of 41 cents in intraday trade today, but with no news from the company since Tuesday, some market watchers are wondering why. At the time of writing, the Imugene share price...

Summary Extending gain for the third session, the ASX200 trades higher by 70 points or 0.51% at 7,059.30. Nuix led the pack with a 9% gain, while St Barbara nosedived over 10%, making it the top loser. Six of 11 sectors traded higher,...

A series of ASX announcements has attracted investors to the biotech sector today, lifting the share prices of some of its players. The buying frenzy has also lifted the broader health sector by as high as 1 per cent earlier today, but is c...

ShareCafeAustralia…1 hour in… ASX200 up 43 ASX200 up 43 points (0.6%) to 7067.   Boral (+0.6%); said it wants to buy US$450m in senior notes following the sale of its 50% share in its joint venture with USG Corp. Crown (-0.1%); the Royal C...

The Imugene Limited (ASX: IMU) share price is leaping higher today on the back of news the immuno-oncology company has entered into a licensing agreement. The agreement will see Imugene licensing the patents for a novel combination immunot...

The company has enhanced its portfolio with novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.

US and European stock markets down to start the week All major indices in US and Europe were down on Monday, after Covid cases spiked in some parts of the world. The Dow Jones was down 0.16%, S&P 500 fell 0.25%, and tech heavy NASDAQ dr...

This week’s Hot Money is more or less brought to you by the good folks at Mindax (ASX:MDX), with a nice cameo from Australia’s only listed football team. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relati...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scr...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Themes of the week Healthcare f...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Google April 2021 and the first things you’ll find isn’t ASX winners but questions about COVID-19. Just another month in the pandemic, right? Well, yes and no. On one hand the vaccine race continues across the world – far slower than we’d l...

HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred.

ShareCafeAustralia…1 hour in… ASX200 down 65 ASX200 down 65 points (0.9%) to 6952.   BHP (-1.8%); reported a 7% drop in Q Iron Ore shipments but still sees FY iron ore output near upper end of forecast. Challenger (-6.4%); still feeling un...

Imugene shares have hit a fresh all-time high this morning after the Sydney biotech said its HER-Vaxx cancer vaccine had achieved a clinical milestone in a phase 2 gastric cancer trial. The 36-patient trial met its secondary endpoint of imp...

In afternoon trade on Monday, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. At the time of writing, the benchmark index is down 0.35% to 6,970.7 points. Four ASX shares that are falling m...

ShareCafeAustralia…1 hour in… ASX200 down 11 ASX200 down 11 points (0.2%) to 6893   BHP (-0.2%); said the decision by its Brazilian joint venture with Vale SA to file for judicial reorganization is a last-resort response to legal actions f...

Singapore-based Asian American Medical Group (ASX:AAJ) was among the small cap names that ran red hot this week. Stockhead’s Hot Money Monday analysis is based on the Relative Strength Index (RSI) — a technical gauge which measures how trad...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

Small caps have gained for a sixth straight day, even as their larger peers declined. The Small Ordinaries index of Australia’s 101st to 300th biggest companies finished the week up 6.7 points, or 0.2 per cent, to a fresh 13-year high of 3,...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…

Imugene (ASX:IMU) shares have hit an all-time high after the Sydney biotech company announced its cancer vaccine was continuing to show early promise in a small clinical trial. A cohort review committee has allowed the Phase 1 trial to move...

The Imugene Limited (ASX: IMU) share price is through the roof today, breaking record highs. At the time of writing, shares in the medical research and development company are up 11.5%, trading at a record high of 14.5 cents each. By compa...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Source: Enjoy The Life, Shutterstock Summary ASX 200 increased 0.8% on Friday, however it edged lower Monday morning with a decline of almost 33% following the quarterly rebalance announcement. ASX 200 saw 6 new companies being added...

The Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company announced an update on its Phase 1 clinical trial of its immunotherapy candidate, PD1-Vaxx. PD1-Vaxx is a B-cell immunotherapy designed to treat...

The company is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy. PD1-Vaxx is a B-cell immunotherapy des...

The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.

Summary Chimeric Therapeutics commenced trading on the ASX today following the successful completion of its IPO. The drug development company raised almost A$35 million from Institutional as well as sophisticated investors. The Compan...

Summary Imugene Limited (ASX:IMU) has completed the recruitment of patients under its ongoing HER-Vaxx Phase 2 clinical trial. Imugene has reduced the overall number of patients under Phase 2 trial to 36 following the IDMC guidance. T...

Imugene Ltd [ASX:IMU] certainly finished 2020 with a bang. With a 5% lift in the IMU share price this morning, the stock is making waves once more. Today, it has since eased back from those record highs, but it is still faring well... The p...

Imugene Limited (ASX: IMU) shares have jumped by 5% in trading so far today after the biotechnology company announced it has completed recruitment for its HER-Vaxx Phase-2 gastric cancer trial. At the time of writing, the Imugene share pri...

ShareCafeAustralia…One Hour In…ASX up 85 points ASX200 up 85 points (1.3%) to 6692. Market tracking better on prospects for more US stimulus after the Democrats won control of the Senate.  Disturbingly,  the focus this morning has been on t...

The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a r...

The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.